HUNTER HEATH III, M.D.
To the editor: Fogelman and colleagues (1) show increased total-body retention of technetium-99m diphosphonate in a small group of patients with primary hyperparathyroidism and equate this finding with evidence of "skeletal disease." They propose this as a ". . . simple, sensitive . . . test in the diagnosis and evaluation of . . . suspected primary hyperparathyroidism." In my opinion, their logic is flawed and their conclusions premature, if not inappropriate. Several specific criticisms follow.
1. The authors state that their method "can differentiate patient groups with renal osteodystrophy, osteomalacia, Paget's disease, and primary hyperparathyroidism from a control population"
Learn more about subscription options.
Register Now for a free account.
HEATH H. Technetium-99m Diphosphonate Retention in Hyperparathyroidism. Ann Intern Med. 1980;92:873–874. doi: 10.7326/0003-4819-92-6-873
Download citation file:
Published: Ann Intern Med. 1980;92(6):873-874.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only